Icon PLC
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Icon PLC
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
0.01%
ICLR weight · VT
No other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: Iqvia Holdings Inc., Incyte Corp, Charles River Laboratories International, Inc. and 3 more; no measured co-movers for Icon PLC.
Same SIC code · 6
Same SEC industry code: Iqvia Holdings Inc., Incyte Corp, Charles River Laboratories International, Inc. and 3 more; no measured co-movers for Icon PLC.
Annual filing, covered
20-F parsed · May 27 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
13F holdings, not covered
Load failed · retrying
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · May 27 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
13F holdings, not covered
Load failed · retrying
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Icon PLC
203.77
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
News
| Manager | Value | % base | |
|---|---|---|---|
| Artisan Partners Limited Partnership | $1.5B | 10.61% | +4.32% |
| Wellington | $924.1M | 6.54% | −10.03% |
| FMR | $915.7M | 6.48% | +26.29% |
| Invesco | $914.5M | 6.47% | new |
| Harris Associates L P | $776.2M | 5.49% | +2.68% |
| Manager | Value | % base | |
|---|---|---|---|
| Artisan Partners Limited Partnership | $1.5B | 10.61% | +4.32% |
| Wellington | $924.1M | 6.54% | −10.03% |
| FMR | $915.7M | 6.48% | +26.29% |
| Invesco | $914.5M | 6.47% | new |
| Harris Associates L P | $776.2M | 5.49% | +2.68% |
+6.76%
shares held · 10 largest managers
Expected move
No implied move.